Abstract
Study objectives: We evaluate the efficacy and tolerability of ziprasidone in acute bipolar mania, focusing on clinically relevant subgroups. Methods: This was a pooled analysis of 2 randomized, double-blind, 21-day trials comparing flexible-dose ziprasidone (40 to 80 mg twice daily) with placebo in adults with mania associated with bipolar I disorder. Changes in Mania Rating Scale (MRS) score and Clinical Global Impression of Severity (CGI–S) were calculated for combined study populations and in subgroups of patients with manic episodes, mixed episodes, and with or without psychotic symptoms. Results: At last visit, mean change in MRS score in patients receiving ziprasidone (n=268) was −11.72 (baseline 26.82) versus −6.69 (baseline 26.53) in patients receiving placebo (n=131; P P P Conclusion: Ziprasidone rapidly improves symptoms and global illness severity in bipolar mania. It is comparably efficacious in mixed and manic episodes and in the presence or absence of psychotic symptoms and is well tolerated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
